Journal of Chemical and Pharmaceutical Research (ISSN : 0975-7384)

Reach Us +44 1625708989
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Original Articles: 2016 Vol: 8 Issue: 6

Antidiabetic action and significant cell viability of bezafibrate-in HEPG2 cell line analysis compared with a biguanide-A potential in the treatment of metabolic syndrome/syndrome X


Metabolic Syndrome (MetS) has been highlighted as a major socioeconomic problem throughout the world as the burden of MetS along with its individual risk factors-central obesity, insulin resistance, dyslipidaemia, and hypertension is evident throughout all ethnicities studies. This study was conducted to evaluate the anti-diabetic property and the cell viability of Bezafibrate, an activator of Lipoprotein Lipase(LPL), when compared to a standard drug used in the treatment of type II Diabetes Mellitus, Metformin ( Biguanide – Oral Hypoglycaemic Agent). In-Vitro analysis with HepG2 tissue culture was done. Glucose consumption of the test drug Bezafibrate was analysed using Glucose oxidase method and the cell viability was determined by MTT [3-(4, 5-dimethylthiazol-2-yl)- 2, 5-diphenyl tetrazolium bromide] assay. The test drug Bezafibrate showed increased glucose consumption level in HepG2 cell lines and had a higher cell viability percentage than the control drug, Metformin.